|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||6.64 - 6.64|
|52 Week Range||5.92 - 10.78|
|Beta (3Y Monthly)||1.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In 2014 Paul Chaplin was appointed CEO of Bavarian Nordic A/S (CPH:BAVA). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Next, we'll consider...
First commercial program under Bavarian Nordic and Janssen Vaccines & Prevention B.V. collaboration advancing into clinical trialsA therapeutic vaccine may represent a novel.
The multi-site trial, which holds the potential to serve as a registration trial, aims to determine if the combination of BN-Brachyury vaccine and the current standard of care, radiation therapy, results in a clinically meaningful objective response rate (ORR) within 12 months of radiation therapy, a timeframe during which historical controls show an ORR of less than 5% with radiation alone. Radiation has been shown to inflame the tumor, releasing cancer antigens.
The program, which is funded by the United States Department of Defense (DoD) Joint Project Management Office for Medical Countermeasure Systems (JPM-MCS) through a multi-year agreement of up to USD 36 million, aims to develop a vaccine against three separate strains of the equine encephalitis virus, Eastern (EEEV), Venezuelan (VEEV), and Western (WEEV), for which there are currently no preventative vaccines available. Since award of the contract in March 2018, Bavarian Nordic has received incremental funding to support the preclinical development, GMP manufacturing and most recently the funding to support a dose ranging Phase 1 clinical trial in 45 healthy volunteers.
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA) have exercised another option under the ongoing contract for freeze-dried MVA-BN® smallpox vaccine. The option, valued at USD 44 million, will cover qualification of the new fill-finish facility, currently being established at the Company's manufacturing site in Denmark, as well as transfer and validation of the freeze-drying process. The majority of this contract option is expected to be revenue recognised in 2019 and 2020.
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for the liquid-frozen version of the MVA-BN® for active immunization against smallpox in adults age 18 years and older. The FDA has granted priority review to the BLA, which means that the agency is targeting completion of the review in six months rather than the standard time of ten months. Priority review is granted by the FDA to applications for medicines that, if approved, would offer a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions.
Paul Chaplin became the CEO of Bavarian Nordic A/S (CPH:BAVA) in 2014. First, this article will compare CEO compensation with compensation at similar sized companies. Then we’ll look at a Read More...
Investigator-led study has commenced dosing Immunotherapy candidate CV301 is now being assessed in three clinical trials in combination with checkpoint inhibitors in multiple.
Chordoma is a rare cancer that occurs in the bones of the skull base and spine, resulting in approximately 1,000 new cases being diagnosed in the United States and Europe annually. The brachyury protein has been shown to be universally overexpressed in chordoma tumors, while not being found in most normal tissue.